What happened On October 23, 2026, AJMC published a contributor article titled “Contributor: Medicare's ACO Model Begins, Kidney Care Cannot Be Left Behind.” Based on the source provided, the concrete takeaway remains narrow: the piece frames the start of Medicare’s ACO model as the policy moment and argues that kidney care should not be excluded from that shift. No additional program details, payment figures, or implementation specifics were included in the source text provided here.
Why it matters This is not a transactional read. It is a policy-positioning signal. By tying kidney care to the start of Medicare’s ACO model, the commentary suggests that advocates are trying to influence how accountable care priorities are set as the model gets underway. For industry readers, that matters because kidney care can become a test case for whether ACO-aligned policy discussions broaden beyond primary care-centric cost and quality frameworks.
For payers, providers, and investors, the practical implication is to watch for follow-on discussion from CMS, provider groups, and kidney-focused stakeholders rather than expecting this item itself to change economics overnight. Our take: the article points toward a familiar 2026 dynamic. Disease areas that fear being sidelined in broad payment reform are making their case early. If that pressure builds, analysts will watch whether kidney care is more explicitly addressed in ACO implementation conversations and adjacent Medicare policy design. For employer-side PBM benchmarking, see RxPBM.ai. Detailed drug monographs are at ClinicalRx.ai.
